Here’s what you should know:
1. The approval provides increased reimbursement in the outpatient setting. The pass-through program will become effective Jan. 1, 2019.
2. The remede system is an implantable device that stimulates the phrenic nerve to treat apnea.
3. Respicardia CEO and President Peter Sommerness said, “We are very pleased that CMS will extend supplemental reimbursement of the remede system into the outpatient setting. The majority of remede system procedures are performed in the outpatient setting, so we expect that this payment will provide substantial support to implanting centers.”
More articles on supply chain:
ASCs hand out fewer narcotics after ACDF than hospital surgery centers, study finds
DJO launches 1st outpatient arthroplasty risk assessment tool
75% of anesthesiologists say surgeons’ OR hours should be capped
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
